UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up

Active, not recruitingOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

August 31, 2026

Conditions
Gallbladder Cancer
Interventions
DIAGNOSTIC_TEST

The level of CNV

The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.

Trial Locations (1)

200092

Xinhua Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Changhai Hospital

OTHER

collaborator

Shanghai Changzheng Hospital

OTHER

collaborator

Eastern Hepatobiliary Surgery Hospital

OTHER

collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

Jiangsu Provincial People's Hospital

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

Second Hospital of Jilin University

OTHER

collaborator

West China Hospital

OTHER

collaborator

Southwest Hospital, China

OTHER

collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT06232538 - UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up | Biotech Hunter | Biotech Hunter